FIELD: medicine.
SUBSTANCE: invention describes a method of evaluating an immunosuppressive response rate in children with chronic glomerulonephritis characterised by determining the peripheral blood cell kinetics by flow DNA-cytometry; evaluating a cell fraction in a proliferation phases not less than 0.74% enables to consider the immunosuppressive therapy to be prescribed, and observing a decreased cell level in proliferation phases in 2-3 weeks after the beginning of administration at least in 2 times, the therapy is considered to be effective; the absence of positive dynamics requires dosage change or preparation replacement.
EFFECT: higher accuracy and reduced number of research injures, derived clinical laboratory criteria of immunosuppressive prescription and prediction of a therapeutic effect.
4 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF CLINICAL COURSE OF CHRONIC RENAL INSUFFICIENCY IN CONGENITAL URINOGENITAL MALFORMATIONS | 2010 |
|
RU2422826C1 |
| METHOD FOR PREDICTION OF RISK OF COMPLICATIONS OF CADAVERIC LIVER TRANSPLANTATION IN RECIPIENTS | 2010 |
|
RU2424529C1 |
| METHOD FOR RESTORING AND KEEPING FAMILY HEALTH | 2002 |
|
RU2230558C2 |
| METHOD FOR DETERMINING QUALITATIVE PARAMETERS OF IMMUNOSUPPRESSIVE CELLS IN CANCER PATIENTS | 2020 |
|
RU2752973C1 |
| METHOD OF PREDICTING THE DEVELOPMENT OF METASTASES IN PATIENTS WITH UNRESECTABLE TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2802141C1 |
| METHOD FOR DETERMINING THERAPEUTIC APPROACH IN PATIENTS WITH METASTATIC FORMS AND RECURRENT TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2818730C1 |
| METHOD FOR PREDICTION OF LIFE EXPECTANCY IN PATIENTS WITH METASTATIC TUMORS | 2023 |
|
RU2821659C1 |
| METHOD OF THERAPY OF REMITTENT MULTIPLE SCLEROSIS | 2012 |
|
RU2523058C2 |
| METHOD FOR ASSESSING THE SENSITIVITY OF A TUMOR TO IMMUNO-ONCOLOGICAL DRUGS | 2021 |
|
RU2771760C1 |
| COMPOSITIONS CAUSING SPECIFIC RESPONSE OF CYTOTOXIC T-LYMPHOCYTES, INCLUDING LYMPH-ABLATIVE COMPOUND AND MOLECULE WHICH CONTAINS ANTIGEN SEQUENCES AND IS TARGETED AT SPECIALISED ANTIGEN-PRESENTING CELLS | 2007 |
|
RU2448729C2 |
